Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
123.79
+0.35 (0.28%)
Nov 5, 2024, 1:19 PM EST - Market open
Natera Revenue
Natera had revenue of $413.35M in the quarter ending June 30, 2024, with 58.13% growth. This brings the company's revenue in the last twelve months to $1.36B, up 46.13% year-over-year. In the year 2023, Natera had annual revenue of $1.08B with 31.99% growth.
Revenue (ttm)
$1.36B
Revenue Growth
+46.13%
P/S Ratio
10.85
Revenue / Employee
$413,150
Employees
3,293
Market Cap
15.31B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tenet Healthcare | 20.97B |
Universal Health Services | 15.42B |
Viatris | 15.24B |
Avantor | 6.82B |
Incyte | 4.08B |
Align Technology | 3.96B |
Genmab | 2.73B |
Revvity | 2.72B |
NTRA News
- 4 days ago - Natera to Report its Third Quarter 2024 Results on November 12, 2024 - Business Wire
- 5 days ago - Cigna Turns $739 Million Profit Despite $1 Billion Loss On VillageMD - Forbes
- 14 days ago - Natera to Present New Renasight Data at ASN Kidney Week 2024 - Business Wire
- 6 weeks ago - Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase - Business Wire
- 7 weeks ago - Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO - Business Wire
- 7 weeks ago - First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival - Business Wire
- 2 months ago - Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival - Business Wire
- 2 months ago - Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Business Wire